Clinical Trial Update: A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of ABT-263 in relapsed or refractory lymphoid malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Lymphoid Leukemia
• Lymphoid Malignancies
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• ABT-263 (navitoclax)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Lymphoid Leukemia, Lymphoid Malignancies | Phase 1, Phase 2 | Status: COMPLETED